Wednesday, December 24, 2025 | 11:56 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Pharma Stocks

Ajanta Pharma hits over 5-month high after partnering with Biocon

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market Semaglutide

Ajanta Pharma hits over 5-month high after partnering with Biocon
Updated On : 24 Dec 2025 | 11:45 AM IST

Why did Emcure Pharma share price rise 2% in overall muted market?

At 9:25 AM, Emcure Pharma share price continued to trade 1 per cent higher at ₹1,392, even as BSE Sensex trade flat with a negative bias at 85,509.78 levels.

Why did Emcure Pharma share price rise 2% in overall muted market?
Updated On : 23 Dec 2025 | 9:41 AM IST

Why did Sudeep Pharma plunge 6% in trade today? Key details inside

Sudeep Pharma share price fell on reporting a weak set of results in the September quarter of financial year 2026 (Q2FY26).

Why did Sudeep Pharma plunge 6% in trade today? Key details inside
Updated On : 22 Dec 2025 | 9:51 AM IST

Sharekhan upgrades Divi's Labs to 'Buy' on strong FY26-28 growth visibility

The brokerage said Divis Laboratories is entering a stronger growth phase, supported by a robust H2FY26 pipeline and visibility for scale-up over the next two years.

Sharekhan upgrades Divi's Labs to 'Buy' on strong FY26-28 growth visibility
Updated On : 11 Dec 2025 | 11:39 AM IST

Biocon-BBL merger positioned to add value, says Nuvama; retains 'Buy' call

The optimism stems from the company's plan to increase its stake in Biocon Biologics (BBL), the expected consolidation of the Biologics arm, and improving fundamentals

Biocon-BBL merger positioned to add value, says Nuvama; retains 'Buy' call
Updated On : 09 Dec 2025 | 8:31 AM IST

Biocon stock tanks 6% on heavy volumes; what's triggered the sell-off?

The board of directors of Biocon are scheduled to meet on December 06, 2025, to consider and approve the proposals for investment in Biocon Biologics, an unlisted material subsidiary of the company.

Biocon stock tanks 6% on heavy volumes; what's triggered the sell-off?
Updated On : 04 Dec 2025 | 1:32 PM IST

Emkay predicts strong upside in Ipca Labs shares on India, export growth

Emkay Global initiated coverage of Ipca Labs shares with 'Buy' rating and a share price target of ₹1,700 -- a 19 per cent upside from current levels

Emkay predicts strong upside in Ipca Labs shares on India, export growth
Updated On : 03 Dec 2025 | 8:41 AM IST

US portfolio, margin expansion to drive gains for pharma major Lupin

Complex generics and better mix fuel recovery cycle

US portfolio, margin expansion to drive gains for pharma major Lupin
Updated On : 02 Dec 2025 | 9:56 PM IST

Wockhardt soars 19% on huge volumes; here's why the pharma stock rose today

The company said the United States Food and Drug Administration (USFDA) has formally accepted the New Drug Application (NDA) for its first-in-class antibiotic 'Zaynich'

Wockhardt soars 19% on huge volumes; here's why the pharma stock rose today
Updated On : 01 Dec 2025 | 2:00 PM IST

Sudeep Pharma makes positive D-St debut; lists at 23% premium on bourses

Sudeep Pharma shares opened at ₹733.95, a premium of ₹140.95 or 23.8 per cent

Sudeep Pharma makes positive D-St debut; lists at 23% premium on bourses
Updated On : 28 Nov 2025 | 10:44 AM IST

SMS Pharma up 8% as arm gets USFDA nod for reformulated Ranitidine tablets

At 10:40 AM, SMS Pharmaceuticals share price was trading 6.77 per cent higher at ₹292.55 per share. In comparison, BSE Sensex was trading 0.73 per cent higher at 85,204.25 levels.

SMS Pharma up 8% as arm gets USFDA nod for reformulated Ranitidine tablets
Updated On : 26 Nov 2025 | 11:11 AM IST

Sun Pharma sees Golden Cross; other pharma stocks with similar pattern

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

Sun Pharma sees Golden Cross; other pharma stocks with similar pattern
Updated On : 26 Nov 2025 | 10:59 AM IST

Glenmark Pharma stock gains 3% on launch novel COPD treatment; details here

The company has launched Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, world's first nebulised, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

Glenmark Pharma stock gains 3% on launch novel COPD treatment; details here
Updated On : 25 Nov 2025 | 11:40 AM IST

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds
Updated On : 25 Nov 2025 | 9:02 AM IST

IT, pharma to gain most from rupee fall; don't jump to buy yet: Analysts

On Monday, the rupee advanced amid reports that the RBI resumed efforts to support currency via overseas and onshore markets

IT, pharma to gain most from rupee fall; don't jump to buy yet: Analysts
Updated On : 24 Nov 2025 | 10:18 PM IST

Glenmark Pharma shares rise after 72% Q2 profit jump; check outlook here

Glenmark Pharma shares rose after the company reported a 72.2 per cent surge in profit after tax to ₹610.43 crore in September quarter

Glenmark Pharma shares rise after 72% Q2 profit jump; check outlook here
Updated On : 17 Nov 2025 | 10:56 AM IST

Ipca Labs jumps 7% after Q2 results; buy, sell or hold? Analysts suggest

Ipca Laboratories share price was trading 6.2 per cent higher at ₹1,382.60 compared to previous session's close of ₹1,302 on the NSE

Ipca Labs jumps 7% after Q2 results; buy, sell or hold? Analysts suggest
Updated On : 14 Nov 2025 | 12:40 PM IST

Lupin share rises 2% as arm commissions Oncology block at Vizag facility

At 1:15 PM, Lupin share price was trading 1.90 per cent higher at ₹2,013.20 per share. In comparison, BSE Sensex was trading 0.91 per cent higher at 84,632.82 levels.

Lupin share rises 2% as arm commissions Oncology block at Vizag facility
Updated On : 12 Nov 2025 | 1:52 PM IST

Nomura lifts Lupin target price on US momentum, India growth recovery

However, on the bourses, Lupin shares were trading 0.70 per cent lower at ₹1,973.50 per share at 9:30 AM. In comparison, BSE Sensex was trading 0.23 per cent lower at 83,346.45 levels.

Nomura lifts Lupin target price on US momentum, India growth recovery
Updated On : 11 Nov 2025 | 9:52 AM IST

Zydus Life Q2: Solid beat on bottom line, analysts mixed on growth outlook

Zydus Life Q2 results review: Foreign brokerage Nomura said Zydus Life delivered results above estimates, led by a stronger-than-expected performance in India.

Zydus Life Q2: Solid beat on bottom line, analysts mixed on growth outlook
Updated On : 07 Nov 2025 | 9:51 AM IST